REG - PureTech Health PLC - PureTech Announces Leadership Transition

Puretech HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nRSP2418Ra&default-theme=true

RNS Number : 2418R  PureTech Health PLC  16 July 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED

 

16 July 2025

PureTech Health plc

 

PureTech Announces Leadership Transition

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to changing the lives of patients with devastating diseases,
announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role
as Chief Executive Officer (CEO) and as a member of the Board of Directors.

 

The Board of Directors has appointed Robert Lyne as Interim CEO with effect
from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January
2024 and is an experienced leader of UK-listed life science innovation and
venture capital companies, having previously served as CEO of Arix Bioscience
plc. He will continue to work closely with PureTech's Board and management
team as the Company delivers on its strategic objectives.

 

Sharon Barber-Lui, Interim Chair of PureTech's Board of Directors, said: "The
Board is grateful to Bharatt for his leadership and dedication to the Company
over the past eight years. On behalf of the Board, I would like to sincerely
thank him for his many contributions and wish him every success in the future.
We remain focused on driving shareholder value, and Rob's extensive
operational and capital markets experience will be key as he collaborates with
the Board and engages with shareholders."

 

Robert Lyne, Interim Chief Executive Officer of PureTech, said: "I am honored
to step into the role of Interim CEO and to continue working with this
exceptional team at such an exciting time for the Company. PureTech has a
high-value portfolio, and I look forward to building on the momentum we've
generated as we advance our programs and deliver on meaningful milestones to
create value for patients and shareholders."

 

Dr. Bharatt Chowrira, said: "It has been a true privilege to be part of
PureTech's journey over the past eight years, including as CEO. I'm incredibly
proud of what we've accomplished together-from advancing innovative science to
progressing breakthrough clinical programs-and I leave with full confidence in
the strength of the team and the exciting opportunities ahead for PureTech."

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep portfolio through its
experienced research and development team and its extensive network of
scientists, clinicians, and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration-enabling studies. All of the underlying
programs and platforms that resulted in this portfolio of therapeutic
candidates were initially identified or discovered and then advanced by
the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation statements that relate to our expectations around
our therapeutic candidates and approach towards addressing major diseases, our
plans to advance our programs and deliver on our milestones, our future plans,
prospects, developments, and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2024 filed with the SEC and in
our other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAFXKFAASEEA